TREA

Point-of-care diagnostic device

Follow

Information

  • Patent Grant
  • D800912
  • Patent Number
    D800,912
  • Date Filed
    Friday, June 17, 2016
    8 years ago
  • Date Issued
    Tuesday, October 24, 2017
    7 years ago
  • US Classifications
    Field of Search
    • US
    • D24 216
    • D24 107
    • D24 169
    • D24 186
    • D24 231
    • D24 232
    • D24 233
    • D10 81
    • CPC
    • G01N2035/00306
    • G01N2035/00326
    • G01N2035/00336
    • G01N33/53
    • G01N33/5302
    • G01N33/569
    • C12Q1/686
    • B01L7/52
  • International Classifications
    • 2401
    • Term of Grant
      15Years
Information
Abstract
Description


FIG. 1 is a top perspective view of the point-of-care diagnostic device, as seen from the top, front, and side;



FIG. 2 is a top plan view thereof;



FIG. 3 is a front elevation view thereof;



FIG. 4 is a right side elevation view thereof;



FIG. 5 is a left side elevation view thereof;



FIG. 6 is a rear elevation view thereof;



FIG. 7 is a bottom plan view thereof; and,



FIG. 8 is a top perspective view of alternative embodiment of the point-of-care diagnostic device, showing the door slid in the open position.


The broken line depiction of a point-of-care device is included for the purpose of illustrating environmental structure and forms no part of the claimed design.


Claims
  • The ornamental design for a point-of-care diagnostic device, as shown and described.
US Referenced Citations (32)
Number Name Date Kind
5281395 Markart et al. Jan 1994 A
5413764 Haar May 1995 A
5567594 Calenoff Oct 1996 A
5885577 Alvarez Mar 1999 A
6146589 Chandler Nov 2000 A
6210901 Seidel et al. Apr 2001 B1
7074888 Miller et al. Jul 2006 B1
8193002 Guo et al. Jun 2012 B2
8507216 Kuroda et al. Aug 2013 B2
9250233 Kipps et al. Feb 2016 B2
D774205 Grace Dec 2016 S
20030068664 Albitar et al. Apr 2003 A1
20050084491 Shealy et al. Apr 2005 A1
20050191620 McDevitt et al. Sep 2005 A1
20050208587 Cardoso et al. Sep 2005 A1
20050272106 Moore et al. Dec 2005 A1
20060008920 Wong et al. Jan 2006 A1
20060068501 Li et al. Mar 2006 A1
20060286379 Gao Dec 2006 A1
20100330585 Kabri et al. Dec 2010 A1
20110117636 Bae et al. May 2011 A1
20110136155 Mehra et al. Jun 2011 A1
20110320130 Valdes et al. Dec 2011 A1
20120220049 Bunce et al. Aug 2012 A1
20120225423 Schwoebel et al. Sep 2012 A1
20130040401 Zin et al. Feb 2013 A1
20130085349 Shaanan et al. Apr 2013 A1
20130130404 Mehra et al. May 2013 A1
20130143246 Nelson et al. Jun 2013 A1
20150293086 Messmer et al. Oct 2015 A1
20150301031 Zin et al. Oct 2015 A1
20160146829 Kipps et al. May 2016 A1
Foreign Referenced Citations (5)
Number Date Country
WO-2007022557 Mar 2007 WO
WO-2009121024 Oct 2009 WO
WO-2012023053 Feb 2012 WO
WO-2015160834 Oct 2015 WO
WO-2016123105 Aug 2016 WO
Non-Patent Literature Citations (69)
Entry
Colman et al. Effects of amino acid sequence changes on antibody-antigen interactions. Research in Immunology 145(1):33-36 (1994).
Dalakas et al. Effect of Alemtuzumab (Campath 1H) in patients with inclusion-body myositis. Brain 132:1536-1544 (2009).
Harlow et al. Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 23-26 (1988).
Lederman et al. A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4. Mol Immunol 28(11):1171-1181 (1991).
U.S. Appl. No. 14/686,578 Office Action dated Oct. 14, 2016.
U.S. Appl. No. 14/981,715 Office Action dated Jul. 12, 2016.
McDade et al. What a Drop Can Do: Dried Blood Spots As a Minimally Invasive Method for Integrating Biomarkers into Population Based Research. Demography 44(4):899-925 (2007).
PCT/US2015/025796 International Preliminary Report on Patentability dated Oct. 27, 2016.
U.S. Serial No. 14/981,715 Office Action dated Jan. 19, 2017.
U.S. Serial No. 15/185,549 Office Action dated Jan. 6, 2017.
Adams et al. Monoclonal antibody therapy of cancer. Nat Biotechnol. 23:1147-1157 (2005).
Barenholz et al. A peptide mimetic of the mycobacterial mannosylated lipoarabinomannan: characterization and potential applications. J Med Microbiol 56(pt 5):579-586 (2007).
Barnett et al. In-Field Implementation of a Recombinant Factor C Assay for the Detection of Lipopolysaccharide as a Biomarker of Extant Life within Glacial Environments. Biosensors (Basel) 2(1):83-100 (2012).
Bazin et al. Rapid visual tests: fast and reliable detection of ochratoxin A. Toxins (Basel) 2(9):2230-2241 (2010).
Beum et al. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J Immunol Methods 289(1-2)97-109 (2004).
Blasco et al. Evaluation of a peptide ELISA for the detection of rituximab in serum. J Immun Methods 325(1-2):127-139 (2007).
Breidenbach et al. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432(7019):925-929 (2004).
Brissette et al. Identification of cancer targets and therapeutics using phage display. Curr Opin Drug Discov Devel 9:363-369 (2006).
Carpino et al. 9-Fluorenylmethoxycarbonyl amino-protecting group. J Org Chem 37(22)3404-3409 (1972).
Co-pending U.S. Appl. No. 15/185,549, filed Jun. 17, 2016.
Co-pending U.S. Appl. No. 29/568,418, filed Jun. 17, 2016.
Degardin et al. Understanding and fighting the medicine counterfeit market. J Pharm Biomed Anal 87:167-175 (2013).
Delano et al. Convergent solutions to binding at a protein-protein interface. Science 287(5456):1279-1283 (2000).
Ding et al. Endotoxin detection—from limulus amebocyte lysate to recombinant factor C. Subcell Biochem 53:187-208 (2010).
FDA—definition of biological product. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm113522.htm (Jul. 2015).
Feltrup et al. Development of a fluorescence internal quenching correction factor to correct botulinum neurotoxin type a endopeptidase kinetics using SNAPtide. Anal Chem 84(24):10549-10553 (2012).
Fernandez-Salas et al. Botulinum Neurotoxin Serotype a Specific Cell-Based Potency Assay to Replace the Mouse Bioassay. PLoS One 7(11):e49516 (2012).
Golden et al. Extended result reading window in lateral flow tests detecting exposure to Onchocerca volvulus: a new technology to improve epidemiological surveillance tools. PLoS One 8(7):e69231 (2013).
Hale et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104(4):948-955 (2004).
Hale. Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein. Immunotechnology 1(3-4):175-187 (1995).
Jiang et al. A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2 J Biol Chem 280(6):4656-4662 (2004).
Jilani et al. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. Leuk Res 28(12):1255-1262 (2004).
Joiner et al. Comparison of Endotoxin Testing Methods for Pharmaceutical Products. Int J Pharm Compd 6:408-409 (2002).
Jones et al. Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins. J Immunol Meth 329(1-2):92-101 (2008).
Kosik et al. Studies of enzymatic cleavage of cellulose using polysaccharide analysis by carbohydrate gel electrophoresis (PACE). Methods Enzymol 510:51-67 (2012).
Laderman et al. Rapid, sensitive, and specific lateral-flow immunochromatographic point-of-care device for detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in serum and whole blood. Clin Vaccine Immunol. 15(1):159-163 (2007).
Lee et al. Performance improvement of the one-dot lateral flow immunoassay for aflatoxin B1 by using a smartphone-based reading system. Sensors (Basel) 13(4):5109-5116 (2013).
Lonza Limulus Amebocyte Lysate (LAL) QCL-1000. Available from: http://bio.lonza.com/uploads/txmwaxmarketingmaterial/Lonza ManualsProductInstructions CL-1000 Product Insert.pdf (2007).
Maloney et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90(6):2188-2195 (1997).
Manshouri et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101(7):2507-2513 (2002).
Merrifield. Solid Phase Peptide Synthesis I. J Am Chem Soc 85:2149-2154 (1963).
Messmer et al. Specific blocking to improve biopanning in biological samples such as serum and hybridoma supernatants. Biotechniques 30(4):798-802 (2001).
Messmer et al. Two human neonatal IgM antibodies encoded by different variable-region genes bind the same linear peptide: evidence for a stereotyped repertoire of epitope recognition. J Immun 162(4):2184-2192 (1999).
Montagna et al. A new sensitive enzyme-linked immunosorbent assay (ELISA) for Alemtuzumab determination: development, validation and application. Int J Immunopathol Pharmacol 20(2):363-371 (2007).
Mulvaney et al. Incorporating fluorescent dyes and quantum dots into magnetic microbeads for immunoassays. Biotechniques. 36(4):602-609 (2004).
Nakamura et al. Lipopolysaccharide-sensitive serine-protease zymogen (factor C) found in Limulus hemocytes. Isolation and characterization. Eur J Biochem 154:511-521 (1986).
Nakano et al. ELISAs for free human immunoglobulin light chains in serum: improvement of assay specificity by using two specific antibodies in a sandwich detection method. J Immunol Methods 293:183-189 (2004).
Ouimet et al. Comparison of Fluorigenic Peptide Substrates PL50, SNAPtide, and BoTest A/E for BoNT/A Detection and Quantification: Exosite Binding Confers High-Assay Sensitivity. Journal of Biomolecular Screening 18(6):726-735 (2013).
PCT/US2009/038674 International Preliminary Report on Patentability dated Sep. 28, 2010.
PCT/US2009/038674 International Search Report and Written Opinion dated Dec. 24, 2009.
PCT/US2015/025796 International Search Report and Written Opinion dated Aug. 21, 2015.
PCT/US2016/14924 International Search Report and Written Opinion dated Apr. 8, 2016.
Perosa et al. Identification of an antigenic and immunogenic motif expressed by two 7-merrituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapy. J Immunol 179(11):7967-7974 (2007).
Pierce® LAL Chromogenic Endotoxin Quantitation Kit. Available from: https://www.piercenet.com/instructions/2162445.pdf (2013).
Poras et al. Detection and Quantification of Botulinum Neurotoxin Type A by a Novel Rapid In Vitro Fluorimetric Assay. Applied and Environmental Microbiology 75(13):4382-4390 (2009).
Rebello et al. Pharmacokinetics of CAMPATH-1H: assay development and validation. J Immunol Methods 260(1-2):285-302 (2002).
Rohr et al. Immunoassay employing surface-enhanced Raman spectroscopy. Anal Biochem 182(2):388-398 (1989).
Sanchez et al. A general process for the development of peptide-based immunoassays for monoclonal antibodies. Cancer Chemother Pharmacol 66(5):919-925 (2010).
Shin et al. Combinatorial solid phase peptide synthesis and bioassays. J Biochem Mol Biol 38(5):517-525 (2005).
Sosnick et al. Distances between the antigen-binding sites of three murine antibody subclasses measured using neutron and X-ray scattering. Biochemistry 31:1779-1786 (1992).
Tan et al. Pharmacokinetics of Cetuximab After Administration of Escalating Single Dosing and Weekly Fixed Dosing in Patients with Solid Tumors. Clin Cancer Res. 12(21):6517-6522 (2006).
Tian et al. Antigen peptide-based immunosensors for rapid detection of antibodies and antigens. Anal Chem 81(13):5218-5225 (2009).
Titov et al. Development and optimization of immunoassays for the detection of botulinum toxins. Prikl Biokhim Mikrobiol 48(2):249-256 (2012).
Tokunaga et al. Further studies on lipopolysaccharide-sensitive serine protease zymogen (factor C): its isolation from Limulus polyphemus hemocytes and identification as an intracellular zymogen activated by alpha-chymotrypsin, not by trypsin. J Biochem 109:150-157 (1991).
U.S. Serial No. 12/934,624 Office Action dated Aug. 22, 2014.
U.S. Serial No. 12/934,624 Office Action dated Jan. 8, 2014.
U.S. Serial No. 12/934,624 Office Action dated Mar. 27, 2015.
Wang et al. Acute intraocular inflammation caused by endotoxin after intravitreal injection of counterfeit bevacizumab in Shanghai, China. Ophthalmology 120(2):355-361 (2013).
Williams et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 177:7435-7443 (2006).